A Comprehensive Monograph on Omeprazole (DB00338): From Molecular Mechanism to Clinical Practice

Introduction and Drug Identification

Overview and Significance

Omeprazole is a seminal small molecule drug that represents a cornerstone in the management of acid-related gastrointestinal disorders.[1] As the first clinically successful proton pump inhibitor (PPI), its introduction marked a paradigm shift in gastroenterology, offering a level of gastric acid suppression that was significantly more potent and sustained than previously available agents like histamine-2 receptor antagonists (

H2​RAs).[2] Classified chemically as a substituted benzimidazole, omeprazole has demonstrated profound efficacy in treating conditions ranging from gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) to rare hypersecretory states.[1] Its global importance is underscored by its inclusion on the World Health Organization's List of Essential Medicines and its immense prescription volume; in 2022, it was the ninth most commonly prescribed medication in the United States, accounting for over 52 million prescriptions.[6]

Historical Context and Regulatory Milestones

The development of omeprazole by Astra AB (now AstraZeneca) was a landmark achievement in pharmacology. The compound was first patented in 1978 and received its initial approval for medical use in 1988.[6] It was subsequently approved by the U.S. Food and Drug Administration (FDA) on September 14, 1989, under the brand name Prilosec, becoming the first-in-class PPI available for clinical use.[1] This approval paved the way for the development of an entire class of related drugs. A pivotal moment in its lifecycle occurred in June 2003, when the FDA approved an over-the-counter (OTC) formulation, Prilosec OTC, making this potent acid-suppressing agent directly accessible to consumers for the treatment of frequent heartburn.[10] This transition from prescription-only to OTC status reflected its well-established efficacy and safety profile for short-term use and significantly broadened its market presence.[4]

Chemical and Physical Properties

Omeprazole is a synthetic organic compound identified as a racemic mixture of its (R)- and (S)-enantiomers.[7] This chirality is clinically relevant, as the isolated (S)-enantiomer was later developed as a separate drug, esomeprazole.[6] The fundamental chemical and physical characteristics of omeprazole are critical to understanding its formulation and pharmacological behavior.

---

Table 1: Physicochemical and Identification Data for Omeprazole

Property	Value	Source(s)
DrugBank ID	DB00338	1
Type	Small Molecule	1
IUPAC Name	5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-benzimidazole	6
CAS Number	73590-58-6	2
UNII	KG60484QX9	2
Molecular Formula	C17​H19​N3​O3​S	13
Molecular Weight	345.42 g/mol	13
Appearance	White to off-white crystalline powder	2
Melting Point	Approximately 156 °C (with decomposition)	2
Solubility	Freely soluble in ethanol and methanol; slightly soluble in acetone and isopropanol; very slightly soluble in water.	2

---

Comprehensive Pharmacological Profile

Pharmacodynamics: Mechanism of Action

The therapeutic effect of omeprazole is derived from its specific and potent inhibition of the final step in gastric acid production. This mechanism is distinct from that of other antisecretory agents and is central to its clinical efficacy.

The Gastric Proton Pump (H+/K+-ATPase)

The primary target of omeprazole is the hydrogen-potassium adenosine triphosphatase (H+/K+-ATPase) enzyme system, commonly referred to as the gastric "proton pump".[1] This enzyme is located exclusively on the secretory surface of gastric parietal cells and functions as the final common pathway for the secretion of hydrochloric acid (HCl) into the gastric lumen.[1] The pump actively transports hydrogen ions (

H+) out of the parietal cell in exchange for potassium ions (K+) from the gastric lumen, an energy-dependent process that ultimately results in the high acidity of stomach contents.[1]

Bioactivation of a Prodrug

Omeprazole is administered as a pharmacologically inactive prodrug.[5] As a weak base, it is absorbed from the small intestine into the systemic circulation and is then preferentially concentrated within the highly acidic environment of the parietal cell's secretory canaliculi.[6] This acidic milieu is the critical site of its activation. The low pH catalyzes a proton-mediated chemical rearrangement of the omeprazole molecule, transforming it into its active form, a reactive tetracyclic sulfenamide.[6] This site-specific activation ensures that the drug's inhibitory action is highly targeted to the gastric parietal cells, minimizing off-target effects.

Irreversible Enzyme Inhibition

The activated sulfenamide metabolite is the key to omeprazole's potent and long-lasting effect. It rapidly forms a stable, covalent disulfide bond with sulfhydryl groups of cysteine residues on the extracytoplasmic domain of the H+/K+-ATPase's alpha subunit.[1] The primary site of this binding has been identified as cysteine 813.[5] This covalent linkage results in the irreversible inactivation of the enzyme pump.[6]

This irreversible "hit-and-run" mechanism explains the apparent paradox between omeprazole's short plasma half-life (0.5 to 1 hour) and its prolonged duration of antisecretory action (up to 72 hours).[6] The drug does not need to remain in the bloodstream to exert its effect; once the pump is inhibited, acid secretion can only be restored through the de novo synthesis of new

H+/K+-ATPase enzyme units by the parietal cell. This cellular turnover process takes approximately 18 to 24 hours, providing a basis for the efficacy of once-daily dosing.[19]

Antisecretory Effects

The direct consequence of proton pump inhibition is a profound and dose-related reduction in gastric acid secretion. This inhibition affects both basal acid output (the continuous, low-level secretion between meals) and stimulated acid secretion, which is triggered by stimuli such as food, gastrin, or histamine.[1] Following oral administration, the onset of this antisecretory effect is rapid, typically occurring within one hour, with the maximum effect observed by two hours.[1] With repeated once-daily dosing, the inhibitory effect accumulates and reaches a plateau after approximately four days, providing consistent and powerful acid control.[1]

Pharmacokinetics: ADME Profile

The absorption, distribution, metabolism, and excretion (ADME) profile of omeprazole is characterized by several key features that influence its clinical use, including its formulation, metabolic pathway, and the significant impact of genetic factors.

Absorption

Omeprazole is an acid-labile compound, meaning it is rapidly degraded in the highly acidic environment of the stomach.[1] To overcome this, oral formulations are designed to protect the active ingredient until it reaches the more alkaline environment of the small intestine. This is achieved through the use of enteric-coated granules contained within delayed-release capsules or tablets.[1] Once the granules pass through the stomach and the enteric coating dissolves, absorption of omeprazole from the small intestine is rapid, with peak plasma concentrations (

Cmax​) typically achieved within 0.5 to 3.5 hours.[1]

The absolute bioavailability after a single oral dose of 20-40 mg is approximately 30-40%, which is attributed to significant pre-systemic, or first-pass, metabolism in the liver.[1] However, upon repeated administration, the bioavailability increases to about 60%.[6] This increase is thought to be due to the saturation of the hepatic enzymes responsible for its metabolism, leading to a reduction in the first-pass effect.[16]

Distribution

Once absorbed, omeprazole is highly bound to plasma proteins, primarily albumin, with a binding percentage of approximately 95%.[6] It has a relatively small apparent volume of distribution of about 0.3 to 0.4 L/kg in healthy subjects, suggesting that its distribution is largely limited to the extracellular fluid and that it does not extensively penetrate into tissues, with the notable exception of its targeted accumulation in gastric parietal cells.[1]

Metabolism

Omeprazole is extensively metabolized in the liver by the cytochrome P450 (CYP) enzyme system.[6] The metabolism is primarily mediated by two specific isoenzymes. The main metabolic pathway is dependent on the polymorphically expressed CYP2C19, which is responsible for the formation of hydroxyomeprazole, the major metabolite found in plasma.[1] A secondary pathway, responsible for the formation of omeprazole sulfone, is mediated by the CYP3A4 isoenzyme.[1] The metabolites of omeprazole are pharmacologically inactive, meaning the parent drug is solely responsible for the therapeutic effect.[6]

Excretion

Following hepatic metabolism, the inactive metabolites of omeprazole are eliminated from the body. The primary route of excretion is renal, with approximately 77-80% of an orally administered dose being excreted in the urine.[6] The remaining portion of the dose is found in the feces, having been eliminated primarily through biliary secretion.[6] The plasma elimination half-life (

t1/2​) of omeprazole is short, ranging from 0.5 to 1 hour in healthy individuals.[6] However, in patients with chronic hepatic impairment, the clearance of omeprazole is reduced, and the half-life can be prolonged to approximately 3 hours.[16]

Pharmacogenomics: The Critical Role of CYP2C19 Polymorphism

The clinical response to omeprazole is not uniform across all patients, a variability that is largely explained by genetic differences in its primary metabolic enzyme, CYP2C19. This field of pharmacogenomics is crucial for optimizing omeprazole therapy.

Metabolizer Phenotypes

The gene encoding the CYP2C19 enzyme is highly polymorphic, meaning numerous genetic variants (alleles) exist within the population that can result in altered enzyme activity.[22] Based on their combination of these alleles (diplotype), individuals can be categorized into distinct metabolizer phenotypes:

• Poor Metabolizers (PMs): Individuals with two no-function alleles (e.g., *2/*2), resulting in significantly reduced or absent enzyme activity.[22]
• Intermediate Metabolizers (IMs): Individuals with one normal-function allele and one no-function allele (e.g., *1/*2).[22]
• Normal Metabolizers (NMs): Also known as extensive metabolizers, these individuals have two normal-function alleles (e.g., *1/*1).[22]
• Rapid Metabolizers (RMs): Individuals with one normal-function and one increased-function allele (e.g., *1/*17).[22]
• Ultrarapid Metabolizers (UMs): Individuals with two increased-function alleles (e.g., *17/*17), leading to very high enzyme activity.[22]

The prevalence of these phenotypes varies significantly among different ethnic groups. For example, the PM phenotype is found in approximately 3% of Caucasians but in 15-20% of Asian populations, a factor with major clinical implications for these groups.[6]

Clinical Implications

The CYP2C19 genotype directly dictates the systemic exposure to omeprazole. PMs, who metabolize the drug slowly, exhibit substantially higher plasma concentrations and a larger area under the curve (AUC) compared to NMs from the same standard dose.[23] This leads to more profound and sustained gastric acid suppression. In contrast, UMs clear the drug so rapidly that standard doses may result in sub-therapeutic plasma concentrations and insufficient acid suppression, increasing the risk of treatment failure.[23]

This genetic variability has a profound impact on both the efficacy and the long-term safety of omeprazole therapy. For conditions requiring a high degree of acid suppression, such as the eradication of Helicobacter pylori, the efficacy of standard triple-therapy regimens is significantly higher in PMs than in NMs or UMs, as the sustained high pH enhances antibiotic activity.[24] Conversely, while PMs are more likely to achieve therapeutic success, their chronically elevated drug exposure also places them at a greater theoretical risk for the dose- and duration-dependent long-term adverse effects discussed later in this report, such as bone fractures and nutrient deficiencies. Thus, an individual's CYP2C19 status is a key determinant of their personal risk-benefit profile with omeprazole, highlighting a critical area for the application of personalized medicine.

Dosing Recommendations

In recognition of these effects, clinical guidelines, such as those from the Clinical Pharmacogenetics Implementation Consortium (CPIC), have been developed to guide dosing based on genotype.[22] For

H. pylori eradication in UMs, a 3-fold increase in the standard omeprazole dose may be recommended to overcome the rapid metabolism and achieve adequate acid suppression.[23] For other indications, clinicians are advised to be alert to reduced effectiveness in UMs and consider dose increases if symptoms persist. For PMs on chronic therapy (>12 weeks), once efficacy is achieved, a 50% reduction in the daily dose may be considered to minimize long-term drug exposure and potential side effects, while monitoring for continued efficacy.[23]

Clinical Applications and Therapeutic Efficacy

Omeprazole is a widely prescribed medication with a range of well-established indications for both adult and pediatric populations, primarily centered on the management of conditions caused by or exacerbated by gastric acid.

FDA-Approved Indications

The U.S. Food and Drug Administration has approved omeprazole for several specific uses, which are supported by extensive clinical trial data.[1]

Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE)

Omeprazole is a first-line therapy for GERD. It is indicated for the treatment of heartburn and other symptoms associated with GERD in adults and pediatric patients one year of age and older.[1] For patients with endoscopically diagnosed erosive esophagitis, a complication of GERD, omeprazole is indicated for short-term treatment (4-8 weeks) to promote healing. This indication extends to adults and pediatric patients as young as one month of age.[27] Furthermore, it is approved for the maintenance of healing of EE in adults and children (≥1 year) to prevent recurrence, although controlled studies for maintenance therapy typically do not extend beyond 12 months.[28]

Peptic Ulcer Disease (PUD)

Omeprazole is indicated for the short-term treatment (4-8 weeks) of active duodenal ulcers and active benign gastric ulcers in adults.[1] Its potent acid suppression provides an optimal environment for ulcer healing.[32] Studies have also demonstrated its efficacy in the medical management of giant duodenal ulcers (≥2 cm), a condition historically managed surgically due to high complication rates.[34]

Helicobacter pylori Eradication

Infection with the bacterium H. pylori is a primary cause of PUD. Omeprazole is a key component of eradication regimens, indicated for use in combination with antibiotics to treat patients with H. pylori infection and duodenal ulcer disease, thereby reducing the risk of ulcer recurrence.[1] It is approved in both triple therapy (omeprazole, clarithromycin, and amoxicillin) and dual therapy (omeprazole and clarithromycin) regimens.[28] The role of omeprazole in these regimens is twofold: it alleviates ulcer symptoms and promotes healing by suppressing acid, and it raises the intragastric pH, which enhances the stability and efficacy of the co-administered antibiotics.[1]

Pathological Hypersecretory Conditions

For adults with conditions characterized by excessive gastric acid production, omeprazole is indicated for long-term treatment.[6] This includes Zollinger-Ellison syndrome (caused by a gastrin-secreting tumor), multiple endocrine adenomas, and systemic mastocytosis.[28] In this patient population, omeprazole has proven to be highly effective and safe for controlling severe acid hypersecretion, often in patients who were resistant to H2RAs, and it is considered the drug of choice for this indication.[37]

Other Approved Uses

Omeprazole is also FDA-approved for the reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.[1]

Off-Label and Over-the-Counter (OTC) Uses

Beyond its approved indications, omeprazole is frequently used for other related conditions. Common off-label uses include stress ulcer prophylaxis in hospitalized patients who are not critically ill, the prevention of ulcers induced by nonsteroidal anti-inflammatory drugs (NSAIDs), and the management of Barrett's esophagus, a precancerous condition resulting from chronic GERD.[16]

The OTC formulation of omeprazole (20 mg) has a specific, narrow indication: the treatment of frequent heartburn that occurs two or more days per week in adults.[43] It is intended for a 14-day course of treatment and should not be taken for more than 14 days or more often than every four months without consulting a physician.[44] It is not intended for immediate relief of heartburn symptoms, as it may take 1 to 4 days to achieve its full effect.[44]

Formulations, Dosage, and Administration

Available Formulations

Omeprazole is available in a variety of formulations to meet diverse patient needs.[6] These include:

• Delayed-Release Capsules: Available in 10 mg, 20 mg, and 40 mg strengths.[30]
• Delayed-Release Tablets: Typically available in a 20 mg strength for OTC use.[43]
• Powder for Delayed-Release Oral Suspension: Provided in packets of 2.5 mg and 10 mg for reconstitution, suitable for pediatric patients or adults with difficulty swallowing.[30]
• Intravenous (IV) Injection: For use in hospital settings when oral administration is not feasible.[6]
• Combination Products: Omeprazole is also available in fixed-dose combination products, such as Zegerid (omeprazole with sodium bicarbonate to allow for more rapid absorption) and Konvomep (omeprazole and sodium bicarbonate oral suspension).[6]

Dosing Regimens

Dosage and duration of omeprazole therapy are highly dependent on the indication, patient age, and, in children, body weight. The following table summarizes FDA-approved dosing regimens.

---

Table 2: FDA-Approved Dosing Regimens for Omeprazole

Indication	Patient Population	Recommended Dose	Frequency	Duration of Therapy	Source(s)
Active Duodenal Ulcer	Adults	20 mg	Once Daily	4 weeks; may extend to 8 weeks	28
H. pylori Eradication (Triple Therapy)	Adults	20 mg (with amoxicillin 1000 mg and clarithromycin 500 mg)	Twice Daily	10 days	28
H. pylori Eradication (Dual Therapy)	Adults	40 mg (with clarithromycin 500 mg)	Once Daily (omeprazole); Three Times Daily (clarithromycin)	14 days	28
Active Benign Gastric Ulcer	Adults	40 mg	Once Daily	4 to 8 weeks	28
Symptomatic GERD	Adults	20 mg	Once Daily	Up to 4 weeks	28
	Pediatrics (1-16 years)	5 mg (5 to <10 kg), 10 mg (10 to <20 kg), 20 mg (≥20 kg)	Once Daily	Up to 4 weeks	30
Erosive Esophagitis (Treatment)	Adults	20 mg	Once Daily	4 to 8 weeks	28
	Pediatrics (1-16 years)	5 mg (5 to <10 kg), 10 mg (10 to <20 kg), 20 mg (≥20 kg)	Once Daily	4 to 8 weeks	30
	Pediatrics (1 month to <1 year)	2.5 mg (3 to <5 kg), 5 mg (5 to <10 kg), 10 mg (≥10 kg)	Once Daily	Up to 6 weeks	47
Erosive Esophagitis (Maintenance)	Adults	20 mg	Once Daily	Long-term (controlled studies up to 12 months)	28
	Pediatrics (1-16 years)	5 mg (5 to <10 kg), 10 mg (10 to <20 kg), 20 mg (≥20 kg)	Once Daily	Long-term	30
Pathological Hypersecretory Conditions	Adults	Starting dose: 60 mg; titrated up to 120 mg three times daily	Once Daily (doses >80 mg should be divided)	As long as clinically indicated	28

---

Administration Instructions

To maximize efficacy, omeprazole should be taken on an empty stomach, approximately 30 to 60 minutes before a meal, typically before breakfast.[16] This timing ensures that the drug reaches the parietal cells when the proton pumps are most actively stimulated by food, making them more susceptible to inhibition. The delayed-release capsules and tablets should be swallowed whole and not crushed or chewed, to protect the enteric coating.[16] For patients with dysphagia, the delayed-release capsule can be opened, and the intact granules can be mixed with one tablespoon of a soft, acidic food like applesauce and swallowed immediately without chewing.[16] The powder for oral suspension should be reconstituted with water according to the specific product instructions and administered within 30 minutes.[31]

Safety, Tolerability, and Risk Management

While omeprazole is generally well-tolerated for short-term use, its safety profile has become more nuanced with widespread, long-term use. A comprehensive understanding of its adverse effects, contraindications, and drug interactions is essential for safe prescribing.

Common and Minor Adverse Effects

The most frequently reported adverse effects associated with omeprazole are typically mild and self-limiting.[16] In clinical trials, the most common side effects (incidence >2%) include headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence.[6] In pediatric populations, the safety profile is similar to that of adults, although respiratory system events and fever have been reported more frequently.[16]

Serious and Long-Term Adverse Reactions

The understanding of omeprazole's safety has evolved significantly since its introduction. Initially perceived as exceptionally safe, extensive post-marketing surveillance and numerous observational studies have raised concerns about potential risks associated with chronic (generally defined as use for more than one year) and/or high-dose therapy. This has led to a clinical shift towards greater stewardship, emphasizing the use of the lowest effective dose for the shortest necessary duration.[55]

Bone Health and Fracture Risk

Multiple observational studies have suggested an association between long-term PPI use and an increased risk of osteoporosis-related fractures, particularly of the hip, wrist, and spine.[6] The FDA has issued a safety communication regarding this risk, noting it is highest in patients receiving high doses or therapy for a year or longer.[55] The proposed biological mechanism involves impaired intestinal absorption of dietary calcium, as gastric acid is necessary to solubilize calcium salts for absorption.[60] However, the evidence is not entirely consistent; some studies have failed to demonstrate a clinically meaningful effect of PPIs on bone mineral density (BMD) or markers of bone turnover, suggesting the association may be influenced by confounding factors.[62] Nonetheless, caution is advised, and patients at risk for osteoporosis should be managed according to established guidelines.[55]

Nutrient Malabsorption

Chronic suppression of gastric acid can interfere with the absorption of certain essential nutrients.

• Vitamin B12 (Cyanocobalamin) Deficiency: A well-established risk of long-term omeprazole use (>3 years) is the malabsorption of dietary vitamin B12.[43] Gastric acid and pepsin are required to cleave vitamin B12 from the proteins in food, a necessary first step for its subsequent absorption in the terminal ileum.[64] Chronic hypo- or achlorhydria induced by omeprazole impairs this initial step, which can lead to a gradual depletion of vitamin B12 stores and, if untreated, result in megaloblastic anemia or neurological complications.[65] This interaction does not affect the absorption of unbound, crystalline vitamin B12 from supplements.[64]
• Hypomagnesemia: Although rare, prolonged treatment with PPIs (typically >1 year) has been associated with hypomagnesemia (low serum magnesium levels).[6] The mechanism is believed to involve impaired active transport of magnesium in the intestine. Severe hypomagnesemia can be life-threatening, presenting with neuromuscular symptoms (tetany, tremors) and cardiac arrhythmias.[43]

Infectious Risk

Gastric acid provides a crucial first-line defense against ingested pathogens. By raising intragastric pH, omeprazole may increase susceptibility to certain infections. A significant body of evidence links PPI use with an increased risk of Clostridioides difficile-associated diarrhea (CDAD), a potentially severe form of colitis.[6] The FDA has issued a warning about this association, advising that CDAD should be considered in any PPI-treated patient with persistent diarrhea.[30] An increased risk of community-acquired pneumonia has also been reported, particularly in the initial phase of therapy, though this association remains more controversial.[6]

Renal Complications

There is growing evidence from observational studies linking PPI use with an increased risk of adverse renal events. PPIs are a known cause of acute tubulointerstitial nephritis (AIN), an idiosyncratic, immune-mediated kidney injury that can lead to acute kidney injury (AKI).[43] More recently, large-scale studies have suggested an association between PPI use and an increased risk of incident chronic kidney disease (CKD) and progression of existing CKD.[56] Importantly, this risk appears to exist even in patients who have not had a prior episode of AKI, suggesting a "silent" and gradual pathway to kidney damage that may go undetected.[79]

Other Concerns

• Gastric Malignancy: A critical precaution when initiating omeprazole is to rule out the presence of gastric malignancy. Symptomatic response to PPI therapy does not preclude the presence of an underlying gastric cancer, and the relief of symptoms could delay diagnosis.[6]
• Fundic Gland Polyps: Long-term use of omeprazole may lead to the development of fundic gland polyps, which are typically benign growths on the stomach lining.[43]
• Lupus Erythematosus: There have been reports of new onset or exacerbation of cutaneous and systemic lupus erythematosus in patients taking PPIs. Patients presenting with joint pain and a characteristic skin rash should be evaluated for this condition.[43]

Contraindications and Precautions

The primary absolute contraindication for omeprazole is a known hypersensitivity to the drug or to any other substituted benzimidazole PPIs, as severe reactions like angioedema and anaphylaxis have occurred.[30] Concomitant use with the antiretroviral drug rilpivirine is also contraindicated because the increased gastric pH caused by omeprazole significantly reduces rilpivirine absorption, leading to a loss of virologic response.[45] Similar concerns apply to nelfinavir.[45]

Precautions are warranted in several patient populations. Patients with severe hepatic impairment may require dose adjustments due to reduced drug clearance.[70] Before undergoing an endoscopy, patients may be advised to temporarily stop taking omeprazole, as it can mask findings that would otherwise be detected.[82]

Drug-Drug Interactions

Omeprazole is involved in numerous clinically significant drug-drug interactions, which primarily arise from two mechanisms: its potent inhibition of the CYP2C19 enzyme and its profound effect on gastric pH.

---

Table 3: Clinically Significant Drug Interactions with Omeprazole

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
Clopidogrel	Inhibition of CYP2C19-mediated conversion of clopidogrel (a prodrug) to its active metabolite.	Reduced antiplatelet effect, potentially leading to increased risk of cardiovascular events (e.g., stent thrombosis, myocardial infarction).	Avoid concomitant use. Consider an alternative PPI with less CYP2C19 inhibition (e.g., pantoprazole) or an H2RA.	30
Warfarin	Inhibition of CYP2C19, which metabolizes the less active R(+)-enantiomer of warfarin.	Potential for increased INR and risk of bleeding.	Monitor INR closely, especially upon initiation or discontinuation of omeprazole. Adjust warfarin dose as needed.	30
Methotrexate	Decreased renal clearance of methotrexate (mechanism not fully elucidated; may involve inhibition of renal transporters like BCRP and H+/K+-ATPase).	Elevated serum levels of methotrexate, leading to increased risk of toxicity (e.g., myelosuppression, renal failure), particularly with high-dose therapy.	Avoid concomitant use with high-dose methotrexate. If unavoidable, monitor methotrexate levels and for signs of toxicity. Consider temporarily withholding omeprazole.	30
Antiretrovirals (e.g., Atazanavir, Rilpivirine, Nelfinavir)	Increased gastric pH reduces the absorption of these drugs, which require an acidic environment.	Significantly reduced plasma concentrations of the antiretroviral, leading to loss of virologic response and potential development of drug resistance.	Concomitant use with rilpivirine and nelfinavir is contraindicated. Avoid use with atazanavir.	30
Azole Antifungals (e.g., Ketoconazole, Itraconazole)	Increased gastric pH reduces the absorption of these drugs, which require an acidic environment.	Reduced plasma concentrations and potential therapeutic failure of the antifungal agent.	Avoid concomitant use or administer the antifungal with an acidic beverage (e.g., cola) if possible. Monitor for clinical efficacy.	30
Digoxin	Increased gastric pH may increase the absorption of digoxin.	Increased serum digoxin levels and potential for toxicity.	Monitor serum digoxin concentrations and for clinical signs of toxicity.	30
CYP2C19 Substrates (e.g., Diazepam, Phenytoin, Cilostazol)	Inhibition of CYP2C19-mediated metabolism.	Increased plasma concentrations and potential for toxicity of the co-administered drug.	Monitor for adverse effects and consider dose reduction of the affected drug.	30
CYP Inducers (e.g., St. John's Wort, Rifampin)	Induction of CYP2C19 and CYP3A4.	Decreased plasma concentrations of omeprazole, potentially leading to reduced therapeutic effect.	Avoid concomitant use.	30

---

Interactions via CYP2C19 Inhibition

The most critical interaction in this class involves clopidogrel, an antiplatelet prodrug that requires activation by CYP2C19. Omeprazole is a potent inhibitor of this enzyme and can significantly reduce the conversion of clopidogrel to its active metabolite, thereby diminishing its antiplatelet effect and increasing the risk of major adverse cardiovascular events in patients who rely on clopidogrel for protection.[84] The FDA has issued a boxed warning advising against the concomitant use of these two drugs.[93] Omeprazole can also inhibit the metabolism of other CYP2C19 substrates, such as

warfarin, potentially increasing its anticoagulant effect and bleeding risk, and diazepam and phenytoin, increasing their plasma levels and risk of toxicity.[30]

Interactions via Altered Gastric pH

By profoundly increasing intragastric pH, omeprazole can alter the absorption of numerous drugs whose bioavailability is pH-dependent. It significantly decreases the absorption of medications requiring an acidic environment, such as the antiretrovirals atazanavir and nelfinavir, and the azole antifungals ketoconazole and itraconazole, potentially leading to therapeutic failure.[30] Conversely, it may increase the absorption of other drugs, like

digoxin, necessitating monitoring for toxicity.[30]

Other Significant Interactions

A particularly serious interaction can occur with methotrexate. Concomitant use, especially with high-dose methotrexate therapy, can delay its renal clearance, leading to elevated and prolonged serum concentrations and a heightened risk of severe toxicity.[87] The mechanism is not fully understood but may involve inhibition of renal tubular transporters.[88] It is recommended to temporarily discontinue PPI therapy prior to and during high-dose methotrexate administration.[96]

Comparative Analysis and Market Context

Omeprazole in the PPI Class

Omeprazole was the first PPI, but the class has since expanded to include several other agents. A comparative understanding of their profiles is essential for clinical decision-making.

---

Table 4: Comparative Profile of Common Proton Pump Inhibitors

Feature	Omeprazole (Prilosec)	Esomeprazole (Nexium)	Lansoprazole (Prevacid)	Pantoprazole (Protonix)	Source(s)
Identity	Racemic mixture of (R)- and (S)-enantiomers	Pure (S)-enantiomer of omeprazole	Substituted benzimidazole	Substituted benzimidazole	6
Dose Equivalence (approx.)	20 mg	20 mg (often used at 40 mg for superior effect)	30 mg	40 mg	98
Primary Metabolic Pathway	CYP2C19 >> CYP3A4	CYP2C19 >> CYP3A4	CYP2C19 ≈ CYP3A4	CYP2C19 (with subsequent sulfation)	6
Potential for Clopidogrel Interaction	High (clinically significant inhibition of CYP2C19)	High (clinically significant inhibition of CYP2C19)	Moderate	Low (weaker CYP2C19 inhibitor)	92
OTC Availability (U.S.)	Yes (20 mg)	Yes (20 mg)	Yes (15 mg)	No	11
Available Formulations	Capsule (DR), Tablet (DR), Oral Suspension, IV	Capsule (DR), Oral Suspension, IV	Capsule (DR), Orally Disintegrating Tablet (ODT)	Tablet (DR), Oral Suspension, IV	97

---

Efficacy

At standard, equipotent doses, most large-scale systematic reviews and clinical trials have found no convincing evidence of a clinically significant difference in efficacy among the various PPIs for healing esophagitis or treating symptoms of GERD and PUD.[97] While some industry-sponsored studies have suggested a marginal superiority for esomeprazole over omeprazole, these often used non-equivalent doses (e.g., 40 mg esomeprazole vs. 20 mg omeprazole).[98] The general clinical consensus is that the choice of PPI should be guided by other factors, such as cost and interaction potential, rather than a presumed difference in efficacy.

Metabolism and Interactions

The most significant differentiator among PPIs lies in their metabolism and resulting potential for drug interactions. Omeprazole and its S-enantiomer, esomeprazole, are heavily metabolized by and are potent inhibitors of CYP2C19. This makes them more susceptible to pharmacogenomic variability and more likely to cause clinically significant interactions with other CYP2C19 substrates like clopidogrel.[92] In contrast, pantoprazole is a weaker inhibitor of CYP2C19 and undergoes subsequent sulfation, a non-CYP pathway, making it less prone to such interactions. For this reason, pantoprazole is often considered a safer choice for patients on polypharmacy, particularly those taking clopidogrel.[100]

Regulatory and Commercial Landscape

Omeprazole is marketed globally under a wide array of brand names, with the most prominent being Prilosec in the United States and Losec in other regions.[4] Other common names include Omesec, Antra, and Mopral.[15] The expiration of AstraZeneca's primary patents in 2001 led to the widespread availability of generic omeprazole, which significantly reduced its cost and increased its accessibility.[4] This event also spurred the development and marketing of esomeprazole (Nexium) as a "next-generation" follow-on drug, which, as the purified active isomer, offered a slightly different pharmacokinetic profile.[6] The drug's commercial success, both as a prescription and an OTC product, has made it one of the most widely used medications in the world.

Conclusion and Expert Synthesis

Omeprazole stands as a landmark therapeutic agent, the progenitor of a class of drugs that has fundamentally transformed the management of acid-related gastrointestinal diseases. Its mechanism of action—the targeted, irreversible inhibition of the gastric proton pump—provides a level of acid suppression that is both potent and durable, underpinning its exceptional efficacy across a broad spectrum of clinical indications. For decades, it has been the standard of care for conditions like GERD, peptic ulcer disease, and Zollinger-Ellison syndrome, offering relief and healing to millions of patients.

However, the clinical perspective on omeprazole has matured significantly over time. Its initial reputation as a remarkably safe medication has been tempered by a growing body of evidence from long-term observational studies. The risk-benefit analysis for omeprazole is now understood to be dynamic, heavily influenced by the duration of therapy and the individual patient's baseline risk profile. The potential for long-term complications—including an increased risk of bone fractures, kidney disease, enteric infections, and critical nutrient deficiencies like vitamin B12 and magnesium—cannot be disregarded. This has rightly shifted the clinical paradigm from indefinite use towards a more judicious approach focused on stewardship.

Based on the comprehensive analysis of its profile, three key principles emerge for the modern-day use of omeprazole:

1. The Principle of Appropriate Use: The guiding tenet for prescribing omeprazole should be to use the lowest effective dose for the shortest duration necessary to achieve the therapeutic goal. For many patients with uncomplicated GERD or heartburn, this may mean short-term courses or on-demand therapy rather than continuous, long-term maintenance. The practice of regularly re-evaluating the need for ongoing therapy and actively pursuing "deprescribing" is a critical component of minimizing exposure and mitigating long-term risks.
2. The Importance of Individualization: A one-size-fits-all approach to omeprazole is no longer sufficient. The profound influence of CYP2C19 genetic polymorphisms on its metabolism means that a standard dose can be sub-therapeutic in an ultrarapid metabolizer and excessive in a poor metabolizer. While routine genotyping is not yet standard practice, awareness of this variability is crucial, especially in cases of treatment failure or in populations with a high prevalence of poor metabolizers. Furthermore, a thorough review of a patient's concomitant medications is non-negotiable, given the high potential for clinically significant drug-drug interactions, most notably with clopidogrel and methotrexate.
3. A Balanced Perspective on Risk: While the list of potential adverse effects associated with long-term use is extensive, it is crucial to maintain a balanced perspective. For many of these associations, the absolute risk increase is small, and the evidence is derived from observational studies that cannot definitively establish causality. For patients with severe conditions such as Barrett's esophagus, complicated ulcer disease, or Zollinger-Ellison syndrome, the proven benefits of long-term acid suppression with omeprazole will almost certainly outweigh the potential risks. The role of the clinician is to engage in shared decision-making, clearly communicating both the benefits and the potential harms to allow for an informed choice that aligns with the patient's clinical needs and values.

In summary, omeprazole remains an indispensable tool in the therapeutic armamentarium. Its journey from a revolutionary "miracle drug" to a powerful agent requiring careful and considered long-term management reflects the evolution of modern pharmacology, where efficacy must be continually balanced against a sophisticated and ever-deepening understanding of risk.

Works cited

1. Omeprazole: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 18, 2025, https://go.drugbank.com/drugs/DB00338
2. Omeprazole - PubChem, accessed July 18, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Omeprazole
3. Omeprazole 73590-58-6 | TCI AMERICA - Tokyo Chemical Industry, accessed July 18, 2025, https://www.tcichemicals.com/US/en/p/O0359
4. Omeprazole - American Chemical Society, accessed July 18, 2025, https://www.acs.org/molecule-of-the-week/archive/o/omeprazole.html
5. Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors, accessed July 18, 2025, https://www.jnmjournal.org/journal/view.html?doi=10.5056/jnm.2013.19.1.25
6. Omeprazole - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/Omeprazole
7. omeprazole | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 18, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=4279
8. Generic Prilosec Availability - Drugs.com, accessed July 18, 2025, https://www.drugs.com/availability/generic-prilosec.html
9. Drug Approval Package: Prilosec (Omeprazole) NDA# 019-810s38s50s5, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/019810s38s50s56.cfm
10. DRUG WATCH: Prilosec OTC: Sometimes it all comes down to cost. | Article | NursingCenter, accessed July 18, 2025, https://www.nursingcenter.com/journalarticle?Article_ID=633196&Journal_ID=54030&Issue_ID=633133
11. Recent Rx-to-OTC Product Switches - U.S. Pharmacist, accessed July 18, 2025, https://www.uspharmacist.com/article/recent-rx-to-otc-product-switches
12. CAS Number 73590-58-6 | Omeprazole - Spectrum Chemical, accessed July 18, 2025, https://www.spectrumchemical.com/cas/73590-58-6
13. 3D structure for Omeprazole (DB00338) | DrugBank Online, accessed July 18, 2025, https://go.drugbank.com/structures/small_molecule_drugs/DB00338
14. [Omeprazole (200 mg)] - CAS [73590-58-6] - USP Store, accessed July 18, 2025, https://store.usp.org/product/1478505
15. Omeprazole | CAS 73590-58-6 | SCBT - Santa Cruz Biotechnology, accessed July 18, 2025, https://www.scbt.com/p/omeprazole-73590-58-6
16. Omeprazole - StatPearls - NCBI Bookshelf, accessed July 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK539786/
17. Clinical pharmacology of omeprazole - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/2029801/
18. Omeprazole API Manufacturer and Supplier | CAS 73590-58-6 - Dr. Reddy's, accessed July 18, 2025, https://api.drreddys.com/product/omeprazole
19. What is the mechanism of Omeprazole? - Patsnap Synapse, accessed July 18, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-omeprazole
20. Understanding The Pharmacology Of Omeprazole - Uses, Mechanism Of Action, And Side Effects - YouTube, accessed July 18, 2025, https://www.youtube.com/watch?v=5-lXFNQlSgw
21. US6174548B1 - Omeprazole formulation - Google Patents, accessed July 18, 2025, https://patents.google.com/patent/US6174548B1/en
22. CYP2C19 proton pump inhibitors guideline revised - CPIC, accessed July 18, 2025, https://cpicpgx.org/content/guideline/publication/PPI/2020/CYP2C19_proton_pump_inhibitors_guideline_revised.pdf
23. Omeprazole Therapy and CYP2C19 Genotype - Medical Genetics Summaries - NCBI, accessed July 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK100895/
24. omeprazole - PharmGKB, accessed July 18, 2025, https://www.pharmgkb.org/chemical/PA450704
25. CYP2C19: Omeprazole, accessed July 18, 2025, https://s3.pgkb.org/attachment/omeprazole_CYP2C19_271111.pdf
26. Influence of CYP2C19 Pharmacogenetic Polymorphism on Proton Pump Inhibitor-based Therapies - J-Stage, accessed July 18, 2025, https://www.jstage.jst.go.jp/article/dmpk/20/3/20_3_153/_article/-char/ja/
27. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRILOSEC safely and effe - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022056s022lbl.pdf
28. PRILOSEC® (omeprazole magnesium) for delayed-release oral suspension - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022056s025lbl.pdf
29. medlineplus.gov, accessed July 18, 2025, https://medlineplus.gov/druginfo/meds/a693050.html#:~:text=Prescription%20omeprazole%20is%20used%20to,age%20and%20older%20with%20GERD.
30. PRILOSEC (omeprazole) Label - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s096lbl.pdf
31. Omeprazole (oral route) - Side effects & dosage - Mayo Clinic, accessed July 18, 2025, https://www.mayoclinic.org/drugs-supplements/omeprazole-oral-route/description/drg-20066836
32. Omeprazole: a new drug for the treatment of acid^peptic diseases - Cleveland Clinic Journal of Medicine, accessed July 18, 2025, https://www.ccjm.org/content/ccjom/58/5/418.full.pdf
33. Stomach ulcer - Treatment - NHS, accessed July 18, 2025, https://www.nhs.uk/conditions/stomach-ulcer/treatment/
34. Treatment of Giant Duodenal Ulcers with Omeprazole - AAFP, accessed July 18, 2025, https://www.aafp.org/pubs/afp/issues/2000/0301/p1473a.html
35. Omeprazole - brand name list from Drugs.com, accessed July 18, 2025, https://www.drugs.com/ingredient/omeprazole.html
36. Zollinger-Ellison syndrome - Symptoms and causes - Mayo Clinic, accessed July 18, 2025, https://www.mayoclinic.org/diseases-conditions/zollinger-ellison-syndrome/symptoms-causes/syc-20379042
37. www.tandfonline.com, accessed July 18, 2025, https://www.tandfonline.com/doi/pdf/10.3109/00365528609003090#:~:text=Treatment%20with%20omeprazole%20was%20evaluated,of%20up%20to%202%20years.
38. Omeprazole in the Zollinger-Ellison Syndrome, accessed July 18, 2025, https://www.tandfonline.com/doi/pdf/10.3109/00365528609003090
39. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/2979229/
40. Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES - MDPI, accessed July 18, 2025, https://www.mdpi.com/2072-6694/15/5/1377
41. Use of omeprazole in patients with Zollinger-Ellison syndrome - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/2007355/
42. Omeprazole | Rehab My Patient, accessed July 18, 2025, https://www.rehabmypatient.com/medications/omeprazole
43. Omeprazole Uses, Side Effects, Dosage, Warnings - Drugs.com, accessed July 18, 2025, https://www.drugs.com/omeprazole.html
44. Omeprazole: MedlinePlus Drug Information, accessed July 18, 2025, https://medlineplus.gov/druginfo/meds/a693050.html
45. Prilosec (omeprazole) dosing, indications, interactions, adverse effects, and more, accessed July 18, 2025, https://reference.medscape.com/drug/prilosec-omeprazole-341997
46. Omeprazole 20 mg - DailyMed, accessed July 18, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d8b466e0-a35e-4fba-9d43-4e6c0122e7ad&type=display
47. Omeprazole (Prilosec) Dosages: Forms, Max Dose, Adjustments - GoodRx, accessed July 18, 2025, https://www.goodrx.com/omeprazole/dosage
48. Omeprazole Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 18, 2025, https://www.drugs.com/dosage/omeprazole.html
49. Department of Pharmacy How to prepare Omeprazole 10mg in 5ml oral suspension - Alder Hey Children's Hospital, accessed July 18, 2025, https://www.alderhey.nhs.uk/wp-content/uploads/2023/06/Reconstituting-Omeprazole-10mg-in-5ml-at-home-PIAG392.pdf
50. Omeprazole 2 mg/mL Suspension - U.S. Pharmacist, accessed July 18, 2025, https://www.uspharmacist.com/article/ccuomeprazole-2-mg-ml-suspension
51. About omeprazole - NHS, accessed July 18, 2025, https://www.nhs.uk/medicines/omeprazole/about-omeprazole/
52. 8 Possible Side Effects of Omeprazole - GoodRx, accessed July 18, 2025, https://www.goodrx.com/omeprazole/common-side-effects
53. Omeprazole: Uses & Side Effects - Cleveland Clinic, accessed July 18, 2025, https://my.clevelandclinic.org/health/drugs/19961-omeprazole-tablets
54. Prilosec Label - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022056s001019810s087lbl.pdf
55. Is there an association between Omeprazole (a Proton Pump Inhibitor) and the development of osteoporosis? - Dr.Oracle, accessed July 18, 2025, https://www.droracle.ai/articles/51354/omeprazole-and-osteoporosis-
56. Can Omeprazole Cause Kidney Problems? - GoodRx, accessed July 18, 2025, https://www.goodrx.com/omeprazole/how-omeprazole-impacts-kidneys
57. Common questions about omeprazole - NHS, accessed July 18, 2025, https://www.nhs.uk/medicines/omeprazole/common-questions-about-omeprazole/
58. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study | The BMJ, accessed July 18, 2025, https://www.bmj.com/content/344/bmj.e372
59. FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors, accessed July 18, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump
60. Long-Term Consequences of Chronic Proton Pump Inhibitor Use - U.S. Pharmacist, accessed July 18, 2025, https://www.uspharmacist.com/article/longterm-consequences-of-chronic-proton-pump-inhibitor-use
61. Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7822697/
62. Can We Stop Worrying About PPIs and Bone Health? - Osteoporosis - MedPage Today, accessed July 18, 2025, https://www.medpagetoday.com/resource-centers/osteoporosis/can-we-stop-worrying-ppis-and-bone-health/447
63. Can omeprazole (proton pump inhibitor) cause vitamin B12 deficiency? - Dr.Oracle, accessed July 18, 2025, https://www.droracle.ai/articles/103798/can-omeprazole-causes-b12-deficiency-
64. The Mechanism for Omeprazole Induced Vitamin B12 Deficiency and Risk of Developing Macrocytic Anemia, Hyperhomocysteinemia, and/or Neuropathy? - EBM Consult, accessed July 18, 2025, https://www.ebmconsult.com/articles/vitamin-b12-cobalamin-deficiency-proton-pump-inhibitor-omeprazole-interaction
65. www.nhs.uk, accessed July 18, 2025, https://www.nhs.uk/medicines/omeprazole/side-effects-of-omeprazole/#:~:text=Long%2Dterm%20side%20effects&text=Taking%20omeprazole%20for%20more%20than,ulcers%20and%20pins%20and%20needles
66. Association of Vitamin B12 deficiency with long-term PPIs use: A cohort study - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9577826/
67. Heartburn medicines and B-12 deficiency - Mayo Clinic, accessed July 18, 2025, https://www.mayoclinic.org/diseases-conditions/gerd/expert-answers/heartburn-meds-and-b12/faq-20348628
68. Omeprazole and vitamin B12 deficiency - PubMed, accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/10369631/
69. Omeprazole – Health Information Library | PeaceHealth, accessed July 18, 2025, https://www.peacehealth.org/medical-topics/id/hn-1266002
70. Omeprazole: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 18, 2025, https://www.rxlist.com/omeprazole/generic-drug.htm
71. What is the update on long-term safety evidence with proton pump inhibitor use?, accessed July 18, 2025, https://dig.pharmacy.uic.edu/faqs/2023-2/june-2023-faqs/what-is-the-update-on-long-term-safety-evidence-with-proton-pump-inhibitor-use/
72. Adverse Effects Associated with Proton Pump Inhibitor Use - PMC - PubMed Central, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7887997/
73. Are Proton Pump Inhibitors (PPIs) Safe for Long-Term Use? > News > Yale Medicine, accessed July 18, 2025, https://www.yalemedicine.org/news/proton-pump-inhibitors-ppi
74. Is omeprazole (Prilosec) bad for your kidneys? - Drugs.com, accessed July 18, 2025, https://www.drugs.com/medical-answers/omeprazole-prilosec-bad-kidneys-3561395/
75. PPIs and Kidney Failure: Symptoms, Causes, Treatment, More - Healthline, accessed July 18, 2025, https://www.healthline.com/health/kidney-disease/ppis-and-kidney-failure
76. Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10248387/
77. Heartburn Medicines Associated with Chronic Kidney Disease Risk, accessed July 18, 2025, https://newsnetwork.mayoclinic.org/discussion/heartburn-medicines-associated-with-chronic-kidney-disease-risk/
78. Omeprazole use and risk of chronic kidney disease evolution | PLOS One, accessed July 18, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0229344
79. Popular heartburn drugs linked to gradual yet 'silent' kidney damage - WashU Medicine, accessed July 18, 2025, https://medicine.washu.edu/news/popular-heartburn-drugs-linked-gradual-yet-silent-kidney-damage/
80. Omeprazole Side Effects: Common, Severe, Long Term - Drugs.com, accessed July 18, 2025, https://www.drugs.com/sfx/omeprazole-side-effects.html
81. Omeprazole - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 18, 2025, https://www.pediatriconcall.com/drugs/omeprazole/827
82. Who can and cannot take omeprazole - NHS, accessed July 18, 2025, https://www.nhs.uk/medicines/omeprazole/who-can-and-cannot-take-omeprazole/
83. Drug Interactions between clopidogrel and omeprazole - Drugs.com, accessed July 18, 2025, https://www.drugs.com/drug-interactions/clopidogrel-with-omeprazole-705-0-1750-0.html
84. What are the interactions between omeprazole and Plavix (clopidogrel)? - Dr.Oracle, accessed July 18, 2025, https://www.droracle.ai/articles/132650/taking-omeprazole-and-plavix
85. www.drugs.com, accessed July 18, 2025, https://www.drugs.com/drug-interactions/omeprazole-with-warfarin-1750-0-2311-0.html#:~:text=Using%20warfarin%20together%20with%20omeprazole,to%20safely%20use%20both%20medications.
86. Using warfarin with proton pump inhibitors (PPIs), accessed July 18, 2025, https://www.sps.nhs.uk/articles/using-warfarin-with-proton-pump-inhibitors-ppis/
87. www.sps.nhs.uk, accessed July 18, 2025, [https://www.sps.nhs.uk/articles/managing-interactions-with-methotrexate/#:~:text=Proton%20pump%20inhibitors%20(for%20example,the%20risk%20of%20methotrexate%20toxicity.](https://www.google.com/url?q=https://www.sps.nhs.uk/articles/managing-interactions-with-methotrexate/%23:~:text%3DProton%2520pump%2520inhibitors%2520(for%2520example,the%2520risk%2520of%2520methotrexate%2520toxicity.&sa=D&source=editors&ust=1752829138571094&usg=AOvVaw15RkKLwESvHkXhf_latkKL)
88. Accumulating Evidence for a Drug–Drug Interaction Between Methotrexate and Proton Pump Inhibitors - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3336837/
89. Omeprazole interactions to avoid - SingleCare, accessed July 18, 2025, https://www.singlecare.com/blog/omeprazole-interactions/
90. OMEPRAZOLE oral - MSF Medical Guidelines, accessed July 18, 2025, https://medicalguidelines.msf.org/en/viewport/EssDr/english/omeprazole-oral-16684375.html
91. Taking omeprazole with other medicines and herbal supplements - NHS, accessed July 18, 2025, https://www.nhs.uk/medicines/omeprazole/taking-omeprazole-with-other-medicines-and-herbal-supplements/
92. Clinical relevance of clopidogrel-proton pump inhibitors interaction - PMC, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4419089/
93. PLAVIX® (clopidogrel tablets) for oral use - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020839s078lbl.pdf
94. Does Omeprazole Have Serious Drug Interactions? - Ro, accessed July 18, 2025, https://ro.co/health-guide/omeprazole-drug-interactions/
95. Interaction: Methotrexate and Proton Pump Inhibitors - Medsafe, accessed July 18, 2025, https://www.medsafe.govt.nz/profs/PUArticles/Sept2013MethotrexateAndProtonPump.htm
96. Methotrexate and omeprazole Interactions - Drugs.com, accessed July 18, 2025, https://www.drugs.com/drug-interactions/methotrexate-with-omeprazole-1590-0-1750-0.html?professional=1
97. Full List of PPIs: 6 Proton Pump Inhibitors to Treat Heartburn - GoodRx, accessed July 18, 2025, https://www.goodrx.com/classes/proton-pump-inhibitors/ppi-list
98. Choosing One PPI Treatment Over Another - AAFP, accessed July 18, 2025, https://www.aafp.org/pubs/afp/issues/2007/1101/p1273.html
99. Proton Pump Inhibitors (PPIs) Therapeutic Interchange - Cleveland Clinic Center for Continuing Education, accessed July 18, 2025, https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/pdf/jan-feb06_i9.pdf
100. 25 Years of Proton Pump Inhibitors: A Comprehensive Review - Gut and Liver, accessed July 18, 2025, https://www.gutnliver.org/journal/view.html?doi=10.5009/gnl15502
101. Pantoprazole vs. Omeprazole for GERD: Which One Is Right for Me? - GoodRx, accessed July 18, 2025, https://www.goodrx.com/classes/proton-pump-inhibitors/omeprazole-vs-pantoprazole
102. What Is A Proton Pump Inhibitor? How To Compare PPIs For Acid Reflux - GoodRx, accessed July 18, 2025, https://www.goodrx.com/classes/proton-pump-inhibitors/what-is-a-proton-pump-inhibitor
103. Comparative effectiveness of proton pump inhibitors - Therapeutics Letter - NCBI Bookshelf, accessed July 18, 2025, https://www.ncbi.nlm.nih.gov/books/NBK598449/
104. Guest Post: Comparative effectiveness of proton pump inhibitors | College of Pharmacists of British Columbia, accessed July 18, 2025, https://www.bcpharmacists.org/readlinks/guest-post-comparative-effectiveness-proton-pump-inhibitors
105. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis, accessed July 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2653397/
106. Omeprazole - AstraZeneca/Mitsubishi Tanabe Pharma Corporation - AdisInsight - Springer, accessed July 18, 2025, https://adisinsight.springer.com/drugs/800009351